Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H53NO14 |
| Molecular Weight | 807.8792 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6
InChI
InChIKey=ZDZOTLJHXYCWBA-MQOKZWAMSA-N
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27+,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
7-epidocetaxel (4-epidocetaxel) is an epimer of antitumor agent docetaxel (TAXOTERE). The presence of 7-epidocetaxel in docetaxel injection and in vivo epimerisation has been reported to be the cause for development of tumor resistance to chemotherapy including docetaxel by inducing tumor cell protein cytochrome P450 1B1.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. | 2002 Nov |
|
| Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy. | 2010 Jul |
|
| Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond. | 2013 Oct |
Patents
Sample Use Guides
B16F10 experimental metastasis model using C57BL/6 mice injected with Taxotere® containing 10% 7-epimer showed higher weight loss as compared to Taxotere® containing no epimer at single dose of 40 mg/kg indicating higher systemic toxicity. Incubation of PEGylated liposomes with phosphate buffer saline (pH 7.4) containing 0.1% w/v Tween-80 for 48 h showed better resistance to docetaxel degradation when compared with Taxotere® injection indicating better in vivo stability of liposomal docetaxel. In addition, PEGylated liposomes showed enhanced in vitro cytotoxicity, against A549 and B16F10 cells, than Taxotere®.
Route of Administration:
Parenteral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30165318
Created by
admin on Fri Dec 15 16:59:21 GMT 2023 , Edited by admin on Fri Dec 15 16:59:21 GMT 2023
|
PRIMARY | |||
|
BVQ8BYC7MI
Created by
admin on Fri Dec 15 16:59:21 GMT 2023 , Edited by admin on Fri Dec 15 16:59:21 GMT 2023
|
PRIMARY | |||
|
153381-68-1
Created by
admin on Fri Dec 15 16:59:21 GMT 2023 , Edited by admin on Fri Dec 15 16:59:21 GMT 2023
|
PRIMARY | |||
|
58510442
Created by
admin on Fri Dec 15 16:59:21 GMT 2023 , Edited by admin on Fri Dec 15 16:59:21 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
